Jazz Pharmaceuticals (JAZZ) Misses Q4 EPS by 20c, Offers FY Guidance

Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $4.00, $0.20 worse than the analyst estimate of $4.20. Revenue for the quarter came in at $665.5 million versus the consensus estimate of $639.55 million.

GUIDANCE:

Jazz Pharmaceuticals sees FY2021 EPS of $15.65-$16.86, versus the consensus of $16.78. Jazz Pharmaceuticals sees FY2021 revenue of $2.55-2.7 billion, versus the consensus of $2.56 billion.

For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
• UiPath Inc. (PATH) Reports In-Line Q2 EPS; offers guidance